$AUTL Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.15 up 16.67% YoY
• Reported revenue of $45.69M up 118.37% YoY
• Autolus Therapeutics increased its full year 2026 guidance for AUCATZYL net product revenue to $140 million to $150 million, up from the previous range of $120 million to $135 million.